Wei Zhang

Wei Zhang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Allergy, Asthma & Immunology Research
Verified
Journal Article
Open access
PDF file
QYQi Yuan
Qi Yuan
XJXinyu Jia
Xinyu Jia
MWMin Wang
Min Wang
ZCZhongqi Chen
Zhongqi Chen
TXTingting Xu
Tingting Xu
NJNingfei Ji
Ningfei Ji
Yuan Q, et al. Allergy Asthma Immunol Res. 2024 Jul;16(4):422-433. https://doi.org/10.4168/aair.2024.16.4.422

13 July 2022 in Journal of Computer Assisted Tomography
Verified
Journal Article
Closed access
YZYan Mm Zhong
Yan Mm Zhong
HXHai Xu
Hai Xu
WZWei Zhang
Wei Zhang
HLHai Li
Hai Li
TYTong-Fu Yu
Tong-Fu Yu
YMYuan Mei
Yuan Mei
Objective: The aim of the study is to investigate the diagnostic accuracy of radiomics on iodine maps from dual-energy computed tomography (DECT) in distinguishing lung cancer from benign pulmonary nodules. Methods: This retrospective study was approved by the institutional review board, and written informed consent was waived. A total of 109 patients with 55 malignant nodules and 62 benign nodules underwent contrast-enhanced DECT. Eight iodine uptake parameters on iodine maps generated by DECT were calculated and established a predictive model. Eighty-seven radiomics features of entire tumor were extracted from iodine maps and established a radiomics model. The iodine uptake model and radiomics model were independently built based on the highly reproducible features using the least absolute shrinkage and selection operator method. The diagnostic accuracy of 2 models were assessed using receiver operating curve analysis. For external validation, 47 patients (25 benign and 22 malignant) from another hospital were assigned to testing data set. Results: All iodine uptake features showed significant association with malignancy (P < 0.01) and 2 selected features (mean value of virtual noncontrast images and mean value of vital part on contrast-enhanced image) constituted the iodine model. The radiomics model comprised 2 features (original shape sphericity and original glszm small area high gray level emphasis), which showed good discrimination both in the training cohort (area under the curve, 0.957) and validation cohort (area under the curve, 0.800). Radiomics model showed superior performance than iodine uptake model (accuracy, 89.7% vs 80.6%). Conclusions: Radiomics model extracted from iodine maps provided a robust diagnostic tool for discriminating pulmonary malignant nodules and had high potential in clinical application.

13 July 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
YWYuemin Wu
Yuemin Wu
Runwei GuanRunwei Guan
Runwei Guan
XLXiao Liang
Xiao Liang
WZWei Zhang
Wei Zhang
YJYuqin Jiang
Yuqin Jiang
RGRenhua Guo
Renhua Guo
The aim of the present study was to predict the response of non-small cell lung cancer (NSCLC) patients to immune checkpoint inhibitors (ICIs) by leveraging computed tomography (CT) images using deep learning techniques. Retrospectively, 624 sequential CT images were gathered from 156 patients at Jiangsu Province Hospital, along with their clinical data. The dataset was subsequently partitioned into three groups: training (n=547), validation (n=64), and test (n=64). Moreover, an external validation cohort included 37 CT images from patients at Nanjing Pukou Peoples' Hospital, accompanied by comprehensive clinical data. An advanced Video Vision Transformer (ViViT) model incorporating global self-attention was utilized to analyse patients treated with ICIs and predict their response. The ViViT model's efficacy was evaluated using a confusion matrix and a receiver operating characteristic curve (ROC). Notably, the ViViT model demonstrated predictive prowess for ICIs response, yielding respective areas under the receiver operating characteristic curve (AUC) of 0.74 (95% CI: 0.69-0.78), 0.74 (95% CI: 0.61-0.86), 0.76 (95% CI: 0.62-0.88), and 0.69 (95% CI: 0.5-0.87) in the training, validation, test, and external validation cohorts. The present study illustrates how a deep learning model can provide a non-invasive means to predict clinical outcomes in NSCLC patients undergoing ICIs, potentially transforming personalized treatment approaches for individuals with NSCLC.

11 April 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JSJie Shen
Jie Shen
LZLantian Zhang
Lantian Zhang
SLShuke Li
Shuke Li
XMXiaofei Mu
Xiaofei Mu
TYTongfu Yu
Tongfu Yu
WGWen Gao
Wen Gao
Background: High expression levels of programmed death receptor 1 (PD-1) and its ligand 1 (PD-L1) have been observed in thymic epithelial tumors (TET), suggesting their potential as prognostic indicators for disease progression and the effectiveness of immunotherapy in TET. The conventional method obtaining PD-L1 was challenging due to invasive sampling and tumor heterogeneityMethods: A total of 124 patients with pathologically confirmed TET (57 PD-L1 positive, 67 PD-L1 negative) were retrospectively enrolled and allocated into training and validation cohorts in a ratio of 7:3. Radiomics features were extracted from T1-weighted, T2-weighted fat suppression, and apparent diffusion coefficient (ADC) map images to establish a radiomics signature in the training cohort. Multivariate logistic regression analysis was conducted to develop a combined radiomics nomogram that incorporated clinical, conventional MR features, or ADC model for evaluation purposes. The performance of each model was compared using receiver operating characteristics analysis, while discrimination, calibration, and clinical efficiency of the combined radiomics nomogram were assessed.Results: The radiomics signature, consisting of four features, demonstrated a favorable ability to predict and differentiate between PD-L1 positive and negative TET patients. The combined radiomics nomogram, which incorporates the peri-cardial invasion sign, ADC value, WHO classification, and radiomics signature, showed excellent performance (training cohort: area under the curve [AUC] = 0.903; validation cohorts: AUC = 0.894). The calibration curve and decision curve analysis further confirmed the clinical usefulness of this combined model. The decision curve analysis demonstrated the clinical utility of the integrated radiomics nomogram.Conclusions: The radiomics signature serves as a valuable tool for predicting the PD-L1 status of TET patients. Furthermore, the integration of radiomics nomogram enhances the personalized prediction capability.